At myTomorrows, we believe everyone should be able to access the treatment options which are open to them. We strive to make it easier for physicians and their patients with unmet medical needs to find, get information about, and access pre-approval medicines whenever possible.
We believe that by making the process of accessing pre-approval medicines more transparent, we’ll be able to transform the lives of people all over the world.
To contact us, please visit https://www.mytomorrows.com/en/get-in-contact.
We believe that by making the process of accessing pre-approval medicines more transparent, we’ll be able to transform the lives of people all over the world.
To contact us, please visit https://www.mytomorrows.com/en/get-in-contact.
Location: Netherlands
Employees: 51-200
Total raised: $47.63M
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | Octopus Ve... | octopusven... |
| 16.11.2025 | Avego | avego.com |
| - | EQT Ventur... | eqtventure... |
| - | Balderton ... | balderton.... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 11.11.2025 | - | $29.24M | Avego |
| 10.01.2017 | - | $10.59M | Octopus Ve... |
| 07.11.2014 | - | $5.6M | - |
| 19.02.2014 | - | $2.2M | - |
Mentions in press and media 23
| Date | Title | Description |
| 12.11.2025 | HealthTech Pioneer myTomorrows Lands $29M to Boost Global Patient Access | myTomorrows, a Dutch HealthTech innovator, just secured a $29 million investment from Avego. This capital injection propels its global mission. The company bridges the critical gap between emerging therapies and patients in need. Its AI-dri... |
| 11.11.2025 | myTomorrows: $29 Million Raised To Expand Global Access To Pre-Approval Therapies | myTomorrows announced it has raised $29 million in new growth funding from Avego to scale its AI-enabled platform that connects patients, physicians, trial sites, and BioPharma partners to pre-approval treatments. The company stated that th... |
| 11.11.2025 | As millions await approved therapies, myTomorrows strengthens its global patient-access mission with €25 million | myTomorrows, a Dutch HealthTech company that connects patients with possible pre-approval treatments, today announced the close of a €25 million financing in order to accelerate the global expansion of its AI-driven platform and enhance acc... |
| 11.11.2025 | myTomorrows Secures $29M to Fuel Global Expansion of Pre-Approval Therapy Access | What You Should Know: – myTomorrows, a health technology company that connects patients with all possible pre-approval treatments, today announced the close of a $29 million financing with Avego. Avego’s growth equity investment will fuel t... |
| 25.02.2025 | Streamlining Clinical Trial Search for UK Patients: myTomorrows and PKB Partnership | What You Should Know: – myTomorrows, a global health technology company connecting patients with all possible pre-approval treatment options, today announced a new partnership with Patients Know Best (PKB), a social enterprise and the leadi... |
| 15.01.2025 | Increasing Participation in Muscular Dystrophy Clinical Trials | Michel van Harten M.D., CEO of myTomorrows Muscular Dystrophy (MD) refers to a group of rare genetic conditions that cause progressive muscle weakness and degeneration in patients. Some forms of MD, such as Duchenne Muscular Dystrophy (DMD)... |
| 27.08.2024 | myTomorrows partners with Pancreatic Cancer Europe to streamline clinical trials | myTomorrows, a global health technology company connecting patients with possible treatment options, twill partner with with Pancreatic Cancer Europe, a multi-stakeholder platform that brings together experts from all over Europe with a com... |
| 22.03.2022 | How a Platform-based, Patient-Centric, Triaging Solution Can Accelerate Clinical Trial Recruitment, Upcoming Webinar Hosted by Xtalks | Patients in need of treatment options increasingly expect a frictionless business-to-consumer experience. TORONTO (PRWEB) March 22, 2022 Clinical trial recruitment is transforming in response to change in the world. Seismic events such as t... |
| 10.01.2017 | Amsterdam-based myTomorrows raises €10 million to improve access to drugs in development | Amsterdam-based myTomorrows, a platform to help patients and doctors access drugs in development, has closed a €10 million funding round. The round was led by EQT Ventures and Octopus Ventures, with participation from existing investors Bal... |
| 09.01.2017 | Amsterdam-based myTomorrows raises €10 million to improve access to drugs in development for physicians and patients | Founded to facilitate access to drugs in development for physicians and their patients, myTomorrows today announced a €10 million growth funding round, co-led by EQT Ventures and Octopus Ventures. Existing investors Balderton Capital and So... |
Show more